{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-003214","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.292532+00:00","generated_at":"2026-06-15T04:03:54.668937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phio Q1 net loss $3.6M; cash $9.0M; Phase 1 trial with AgonOx expected Q2 2023","bullets":["Net loss of $3.6M ($3.15 per share) vs $2.6M ($2.34 per share) in Q1 2022.","Cash at March 31, 2023: $9.0M, down from $11.8M at Dec 31, 2022; subsequent equity offering raised ~$1.7M net.","R&D expenses $2.1M (+35% YoY); G&A $1.5M (+39% YoY).","Expects to commence Phase 1 ACT trial with partner AgonOx by end of Q2 2023.","Cash expected to fund operations into Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-003214","json":"https://secwatch.observer/filing/0001683168-23-003214.json","markdown":"https://secwatch.observer/filing/0001683168-23-003214.md","text":"https://secwatch.observer/filing/0001683168-23-003214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/0001683168-23-003214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:03:54.668937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"592bd35a6a7d52756b211203eaeee7e0629b136c","claim":"Phio Pharmaceuticals Corp. reported the quarter ended March 31, 2023 results: net income Net loss increased 36% to approximately $3.6 million, EPS $3.15 per share.","evidence_excerpt":"Net loss increased 36% to approximately $3.6 million, or $3.15 per share, for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/0001683168-23-003214-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss increased 36% to approximately $3.6 million"},{"label":"EPS","value":"$3.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}